Breaking News

GSK Discontinues Development of Anacor Drug

October 5, 2012

Returns all rights, amends R&D pact

GlaxoSmithKline has discontinued development of GSK2251052 following a recent clinical trial that was stopped due to the identification of microbiological findings of resistance in a small number of patients undergoing treatment of complicated urinary tract infections (cUTI). GSK has decided to discontinue further development of GSK2251052 and return all rights to Anacor.
 
Anacor Pharmaceuticals licensed the drug to GSK in July 2010 under an ongoing R&D collaboration. GSK is continuing to fund Anacor’s research activities in tuberculosis as under the companies’ amended R&D collaboration.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.